Bavarian strikes historic Prostvac deal
Denmark’s Bavarian Nordic has signed a historic deal with a potential value of almost 1 billion dollars with one of the world’s leading drug companies concerning its prostate cancer drug Prostvac.
BY LONNI LYNGE & BENJAMIN WERNER CHRISTENSEN
Bavarian Nordic has signed the biggest deal in the history of the company, the Danish biotech company announced Wednesday morning. The deal gives Big Pharma player Bristol-Myers Squibb an exclusive option to license and commercialize Bavarian’s phase III candidate Prostvac, a therapeutic vaccine to treat prostate cancer.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bavarian: Most compelling results so far
For abonnenter
Aamund wants to invest in drug development
For abonnenter
Bavarian: Of course we would like to supply Denmark
For abonnenter
